Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
NL0015436031
Fri, 14.07.2023
CureVac
CureVac Announces Update to the Management Team
TÜBINGEN, Germany / BOSTON, USA – July 14, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that Dr. Igor Splawski, CureVac’s Chief Scientific Officer, [ … ]
Fri, 14.07.2023
CureVac
CureVac Announces Update to the Management Team
TÜBINGEN, Germany / BOSTON, USA – July 14, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that Dr. Igor Splawski, CureVac’s Chief Scientific Officer, [ … ]
Thu, 13.07.2023
CureVac
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases
Under New Intellectual Property Rights
Cases in Germany and the U.S. broadened by asserting additional, new intellectual property rights
Three new intellectual property rights added to infringement lawsuit against Pfizer/BioNTech in Germany, increasing number of asserted [ … ]
Thu, 13.07.2023
CureVac
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases
Under New Intellectual Property Rights
Cases in Germany and the U.S. broadened by asserting additional, new intellectual property rights
Three new intellectual property rights added to infringement lawsuit against Pfizer/BioNTech in Germany, increasing number of asserted [ … ]
Tue, 20.06.2023
CureVac
CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma
Cancer vaccine candidate CVGBM utilizes single mRNA, encoding eight epitopes of tumor-associated antigens with demonstrated relevance in glioblastoma
Study designed to evaluate safety and immunogenicity in patients with glioblastoma aft [ … ]
Tue, 20.06.2023
CureVac
CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma
Cancer vaccine candidate CVGBM utilizes single mRNA, encoding eight epitopes of tumor-associated antigens with demonstrated relevance in glioblastoma
Study designed to evaluate safety and immunogenicity in patients with glioblastoma aft [ … ]
Tue, 20.06.2023
CureVac
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board
TÜBINGEN, Germany / BOSTON, USA – June 20, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the appointment of Mich [ … ]
Tue, 20.06.2023
CureVac
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board
TÜBINGEN, Germany / BOSTON, USA – June 20, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the appointment of Mich [ … ]
Mon, 19.06.2023
CureVac
CureVac Announces Voting Results of General Meeting
TÜBINGEN, Germany / BOSTON, USA – June 19, 2023 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's annual general m [ … ]
Mon, 19.06.2023
CureVac
CureVac Announces Voting Results of General Meeting
TÜBINGEN, Germany / BOSTON, USA – June 19, 2023 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's annual general m [ … ]